GlaxoSmithKline (LON:GSK) has been assigned a GBX 1,775 ($24.89) price objective by equities researchers at Goldman Sachs Group in a research note issued on Thursday. The brokerage presently has a “buy” rating on the stock. Goldman Sachs Group’s price target points to a potential upside of 37.49% from the stock’s current price.
Other equities analysts have also issued research reports about the stock. Beaufort Securities reiterated a “buy” rating and set a GBX 1,800 ($25.24) price target on shares of GlaxoSmithKline in a report on Monday, October 23rd. Liberum Capital reiterated a “buy” rating and set a GBX 1,760 ($24.68) price target on shares of GlaxoSmithKline in a report on Wednesday, October 25th. Jefferies Group lifted their price target on shares of GlaxoSmithKline from GBX 1,675 ($23.49) to GBX 1,700 ($23.84) and gave the stock a “buy” rating in a report on Monday, October 16th. set a GBX 1,925 ($26.99) price target on shares of GlaxoSmithKline and gave the stock a “buy” rating in a report on Thursday, October 26th. Finally, Berenberg Bank dropped their target price on shares of GlaxoSmithKline from GBX 1,835 ($25.73) to GBX 1,760 ($24.68) and set a “buy” rating on the stock in a report on Thursday, November 2nd. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have issued a buy rating to the stock. GlaxoSmithKline has an average rating of “Hold” and an average target price of GBX 1,541.36 ($21.61).
Shares of GlaxoSmithKline (GSK) traded down GBX 12.80 ($0.18) during trading hours on Thursday, hitting GBX 1,291 ($18.10). 11,680,000 shares of the stock were exchanged, compared to its average volume of 9,480,000. The firm has a market capitalization of $64,010.00 and a price-to-earnings ratio of 4,164.52. GlaxoSmithKline has a 52 week low of GBX 1,235.20 ($17.32) and a 52 week high of GBX 1,724.50 ($24.18).
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.